Min Liu

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States
    Biochemistry 50:9399-408. 2011
  2. pmc Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women s Hospital, 65 Landsdowne Street, Fourth Floor, Cambridge, MA 02139, USA
    Anal Biochem 404:186-92. 2010
  3. pmc Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 49:4921-9. 2010
  4. doi request reprint Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 47:8367-77. 2008
  5. pmc Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 49:2008-17. 2010
  6. doi request reprint Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S
    Min Liu
    Harvard NeuroDiscovery Center, Harvard University, 65 Landsdowne Street, 452, Cambridge, Massachusetts 02139, United States
    Biochemistry 52:1725-36. 2013
  7. ncbi request reprint New approaches to the discovery of cdk5 inhibitors
    Marcie A Glicksman
    Laboratory for Drug Discovery for Neurodegeneration, Harvard Center for Neurodegeneration and Repair, Brigham and Women s Hospital and Harvard Medical School, Cambridge, MA, USA
    Curr Alzheimer Res 4:547-9. 2007
  8. pmc Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design
    Soumya Ray
    Brigham and Women s Hospital, 65 Landsdowne Street, Fourth Floor, Cambridge, MA 02139, USA
    Future Med Chem 4:1701-13. 2012
  9. pmc Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors
    Joydev K Laha
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    Bioorg Med Chem Lett 21:2098-101. 2011
  10. doi request reprint A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity
    Justin D Boyd
    1Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital and Harvard Medical School, Cambridge, MA, USA
    J Biomol Screen 19:44-56. 2014

Collaborators

Detail Information

Publications11

  1. pmc Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States
    Biochemistry 50:9399-408. 2011
    ..Finally, the GTPase activity of the t-G2019S mutant was characterized, and the mutation modestly decreases GTPase activity without significantly affecting GTP binding affinity...
  2. pmc Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women s Hospital, 65 Landsdowne Street, Fourth Floor, Cambridge, MA 02139, USA
    Anal Biochem 404:186-92. 2010
    ..An inhibitor identified through the screen was further characterized as a noncompetitive inhibitor with both ATP and PLK-peptide and showed similar inhibition against LRRK2 WT and the mutant G2019S...
  3. pmc Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 49:4921-9. 2010
    ..The pH profile revealed a residue with a pK(a) of 6.5 that is most likely the general acid-base catalyst facilitating the proton transfer...
  4. doi request reprint Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 47:8367-77. 2008
    ..These results contrast with reported claims that APS and CTIU are competitive inhibitors of the binding of ATP...
  5. pmc Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, 65 Landsdowne Street, Fourth Floor, Cambridge, Massachusetts 02139, USA
    Biochemistry 49:2008-17. 2010
    ..Our study revealed that this compound is a competitive inhibitor of the binding of ATP and inhibits the kinase activity without affecting the GTPase activity...
  6. doi request reprint Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S
    Min Liu
    Harvard NeuroDiscovery Center, Harvard University, 65 Landsdowne Street, 452, Cambridge, Massachusetts 02139, United States
    Biochemistry 52:1725-36. 2013
    ..Our results suggest that developing type II inhibitors, which are generally considered superior to type I inhibitors because of desirable selectivity profiles, might be especially challenging for the G2019S LRRK2 mutant. ..
  7. ncbi request reprint New approaches to the discovery of cdk5 inhibitors
    Marcie A Glicksman
    Laboratory for Drug Discovery for Neurodegeneration, Harvard Center for Neurodegeneration and Repair, Brigham and Women s Hospital and Harvard Medical School, Cambridge, MA, USA
    Curr Alzheimer Res 4:547-9. 2007
    ..The hope is that non-ATP competitive compounds will more likely be selective and will be better therapeutics...
  8. pmc Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design
    Soumya Ray
    Brigham and Women s Hospital, 65 Landsdowne Street, Fourth Floor, Cambridge, MA 02139, USA
    Future Med Chem 4:1701-13. 2012
    ..Finally, we discuss the relationship of LRRK2 with tau and α-synuclein. The fact that all three proteins are autophapgy-related provides a future strategy for the identification of LRRK2 physiological substrate(s)...
  9. pmc Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors
    Joydev K Laha
    Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    Bioorg Med Chem Lett 21:2098-101. 2011
    ..Interpretation of the SAR results for many of the analogs was aided through in silico docking with Cdk5/p25 and calculating protein hydrations sites using WaterMap. Finally, improved in vitro mouse microsomal stability was also achieved...
  10. doi request reprint A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity
    Justin D Boyd
    1Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women s Hospital and Harvard Medical School, Cambridge, MA, USA
    J Biomol Screen 19:44-56. 2014
    ..The hits from this assay will be useful for elucidating regulation of TDP-43, stress granule response, and possible ALS therapeutics. ..
  11. ncbi request reprint Development of a fluorescent high throughput assay for tau aggregation
    Min Liu
    Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women s Hospital and Harvard Medical School, Cambridge, MA, USA
    Assay Drug Dev Technol 2:609-19. 2004
    ..A model for tau aggregation is presented. The performance of this assay in a high throughput format is demonstrated and can be used to identify inhibitors of tau aggregation...